文献速递心境障碍

单用抗抑郁药或联合认知行为治疗预防重性抑郁发作康复后复发:两阶段随机临床试验第二阶段的解读

Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2020-01-01

该研究纳入292例慢性或复发性重性抑郁障碍门诊患者,均为第一阶段经抗抑郁药单用或联合认知行为治疗达到康复者。第二阶段随机维持或撤停抗抑郁药并随访3年,结果显示维持抗抑郁药可降低复发率,而第一阶段是否接受认知行为治疗与后续持续康复率无显著关联。

要点

  • 维持抗抑郁药治疗较撤停显著降低抑郁复发率,单用组48.5% vs 74.8%,联合组48.5% vs 76.7%。
  • 第一阶段是否接受认知行为治疗与第二阶段持续康复率无显著差异(OR 1.08,95%CI 0.52-2.11)。
  • 第一阶段治疗条件与第二阶段用药策略间无显著交互作用(OR 1.14,95%CI 0.49-2.88)。

核心结论

  • 维持抗抑郁药治疗与降低抑郁复发率相关,而既往是否接受认知行为治疗与复发预防无显著关联。
  • 认知行为治疗在不联合抗抑郁药时对抑郁复发的预防作用是否适用于复发预防、或加用抗抑郁药是否干扰该效应,尚不明确。

研究设计与样本

  • 两阶段随机临床试验的第二阶段,纳入292例慢性或复发性重性抑郁障碍成年门诊患者(171女,121男,平均年龄45.1岁,SD 12.9)。
  • 第一阶段患者经抗抑郁药单用或联合认知行为治疗达到康复,第二阶段随机接受抗抑郁药维持或撤停并随访3年。

主要发现

  • 第一阶段单用抗抑郁药康复者中,维持治疗组复发率48.5%,撤停组74.8%(z=-3.16,P=.002;NNT 2.8,95%CI 1.8-7.0)。
  • 第一阶段联合认知行为治疗康复者中,维持治疗组复发率48.5%,撤停组76.7%(z=-3.49,P<.001;NNT 2.7,95%CI 1.9-5.9)。
  • 持续康复率维持抗抑郁药优于撤停(z=2.90,P=.004;OR 2.54,95%CI 1.37-4.84;NNT 2.3,95%CI 1.5-6.4)。
  • 第一阶段治疗条件与持续康复率无显著关联(单用 vs 联合:z=0.22,P=.83;OR 1.08,95%CI 0.52-2.11)。
  • 第一阶段与第二阶段治疗条件间无显著交互作用(z=0.30,P=.77;OR 1.14,95%CI 0.49-2.88)。

关键数值与推荐

  • 主要结局为采用纵向间隔随访评估的重性抑郁发作复发及两阶段持续康复。
  • 维持抗抑郁药较撤停的复发率差异:单用康复者48.5% vs 74.8%(P=.002),联合康复者48.5% vs 76.7%(P<.001)。
  • 持续康复率维持抗抑郁药优于撤停(OR 2.54,95%CI 1.37-4.84;NNT 2.3,95%CI 1.5-6.4)。

临床怎么用

  • 对慢性或复发性重性抑郁障碍康复患者,维持抗抑郁药治疗可显著降低复发风险。
  • 不应仅依据既往是否接受认知行为治疗来决定是否维持抗抑郁药,因该因素与持续康复率无显著关联。

局限性

  • 原文未报告第二阶段样本量、随访脱落率及盲法实施细节。
  • 认知行为治疗对复发预防的效应及与抗抑郁药的交互作用仍不明确,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Antidepressant medication (ADM) maintenance treatment is associated with the prevention of depressive recurrence in patients with major depressive disorder (MDD), but whether cognitive behavioral therapy (CBT) treatment is associated with recurrence prevention remains unclear. OBJECTIVE: To determine the effects of combining CBT with ADM on the prevention of depressive recurrence when ADMs are withdrawn or maintained after recovery in patients with MDD. DESIGN, SETTING, AND PARTICIPANTS: A total of 292 adult outpatients with chronic or recurrent MDD who participated in the second phase of a 2-phase trial. Participants had recovered in the first phase of the trial receiving ADM, either alone or in combination with CBT. The trial was conducted in research clinics in 3 university medical centers in the United States. Patients in phase 2 were randomized to receive maintenance of or withdrawal from ADM and were followed up for 3 years. The first and last patients entered phase 2 in August 2003 and October 2009, respectively. The last patient completed phase 2 in August 2012. Data were analyzed from December 2013 to December 2018. INTERVENTIONS: Maintenance of or withdrawal from treatment with ADM. MAIN OUTCOMES AND MEASURES: Recurrence of an MDD episode using longitudinal interval follow-up evaluations; sustained recovery across both phases. RESULTS: A total of 292 participants (171 women, 121 men; mean [SD] age 45.1 [12.9] years) were included in analyses of depressive recurrence. Maintenance ADM yielded lower rates of recurrence compared with ADM withdrawal regardless of whether patients had achieved recovery in phase 1 with ADM alone (48.5% vs 74.8%; z = -3.16; P = .002; number needed to treat [NNT], 2.8; 95% CI, 1.8-7.0) or ADM plus CBT (48.5% vs 76.7%; z = -3.49; P < .001; NNT, 2.7; 95% CI, 1.9-5.9). Sustained recovery rates differed as a function of phase 2 condition, with maintenance ADM superior to ADM withdrawal (z = 2.90; P = .004; OR, 2.54; 95% CI, 1.37-4.84; NNT, 2.3; 95% CI, 1.5-6.4). Phase 1 condition was not associated with differential rates of sustained recovery (ADM alone vs ADM plus CBT; z = 0.22; P = .83; OR, 1.08; 95% CI, 0.52-2.11; NNT, 26.0; 95% CI, number needed to harm 3.2 to NNT 2.8), nor was there a significant interaction of phase 1 condition and phase 2 condition (z = 0.30; P = .77; OR, 1.14; 95% CI, 0.49-2.88). CONCLUSIONS AND RELEVANCE: Maintenance ADM treatment, but not previous exposure to CBT, was associated with reduced rates of depressive recurrence. In previous studies, when CBT has been provided without ADM, CBT has shown a preventive effect on depressive relapse. Whether CBT also has a preventive effect on depressive recurrence, or if adding ADM interferes with any such preventive effect, remains unclear. TRIAL REGISTRATION: ClinicalTrial.gov identifier: NCT00057577.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. DeRubeis RJ, Zajecka J, Shelton RC, et al. Prevention of Recurrence After Recovery From a Major Depressive Episode With Antidepressant Medication Alone or in Combination With Cognitive Behavioral Therapy: Phase 2 of a 2-Phase Randomized Clinical Trial. JAMA Psychiatry. 2020. PMID: 31799993. doi:10.1001/jamapsychiatry.2019.3900

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。